Patients were then re-randomized to either pen or vial-and-syringe for further observation ( 6 , 10 , and 30 weeks ) to evaluate clinical end points ( glycosylated hemoglobin [ A1C ] and fasting blood glucose levels ) and safety outcomes ( hypoglycemia and adverse events ) .